Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Declines By 55.4%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 413,675 shares, a decrease of 55.4% from the April 15th total of 926,778 shares. Based on an average daily trading volume, of 1,653,442 shares, the short-interest ratio is currently 0.3 days. Approximately 6.6% of the company’s stock are sold short.

Avalon GloboCare Stock Down 1.8%

Shares of Avalon GloboCare stock opened at $0.34 on Friday. Avalon GloboCare has a 52 week low of $0.21 and a 52 week high of $4.74. The business has a 50 day moving average price of $0.52 and a 200-day moving average price of $1.00. The company has a market cap of $2.84 million, a PE ratio of -0.10 and a beta of -0.04.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.49) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.